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INTRODUCTION 
One of the tasks of a pharmacologist is the classification of drugs. Marijuana 
and its derivatives pose some problems. Legally marijuana has been classified 
as a narcotic, yet pharmacologically it is quite different. Mankind has known 
about the Cannabis plant from which marijuana and other products are obtained 
for more than 4,708 years. A considerable body of data is available to describe its 
gross effects. Over the centuries it has been called a depressant, euphoriant, ine- 
briant, intoxicant, hallucinogen, psychotomimetic, sedative-hypnotic-anesthetic, 
and stimulant. Perhaps more than any other drug it is a social irritant that 
elicits rather remarkable behavior reactions in both users and nonusers. Moreau’ 
in 1845, employed it to produce a model psychosis, thus initiating the fashion 
to study hallucinogens as a means of gaining insights into mental illness. Lewin2 
classified Cannabis as one of the “phantastica: hallucinating substances.” One 
text on hallucinogens3 does not even refer to Cannabis, but another does? 
There are some aspects of the subjective effects of both LSD-25 and Cannabis 
that are similar, yet the latter produces sedative effects, no significant sympatho- 
mimetic actions, and no cross-tolerance to LSD-25. Hollister5 reviewed the re- 
cent findings on the effects in man of marijuana and its putative active ingredient 
Ag-THC, stressing that current investigators have, for the most part, confirmed 
the Cannabis-induced clinical syndromes long known to occur. New knowledge 
of the active ingredients, biotransformation, dosage, pharmacokinetics, tolerance, 
and cross-tolerance in animals and man is now rapidly accumulating, thanks to 
the medicinal chemists who have provided us with relatively pure compounds 
(see Mechoulama). 
Yet for all the reading one may do about marijuana, there is nothing like the 
experience of personal research. This paper describes some of those experiences 
done first in the 1950s and later in the 1960-70s in animals and, subsequ-ntly, 
in man. The issue of classification is implicit in the attempt to ask what marijuana 
or its pure active derivatives do to various brain functions. Where and how do 
they act, using those limited techniques available in one’s own laboratory? This 
research is due to the efforts of many of my students or associates whose work 
has been or is being published in separate form in the near future. 
ANIMAL STUDIES 
Gross Behavioral Eflects of Various THC Derivatives 
In various animals, A9-THC and the synthetic derivatives, DMHP, pyrahexyl, 
MOP, and NAP show predominant central nervous system depre~sion.’.~ The 
effects of the synthetic THC derivatives last from several hours to days, depend- 
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ing upon the dose administered. During this period animals do not respond in a 
normal manner to painful stimuli. The degree of apparent analgesia is marked. 
Very small doses of the above drugs produce selective CNS depression of the 
dog or monkey free from signs of central excitation or analgesia. Yet, auditory 
and tactile stimuli can produce hyperreactivity. The animals appear to prefer 
to lie quietly, and passively resent being disturbed. Larger doses are required 
to produce a similar response in the monkey than in the dog. With increasing 
doses, a period of initial central nervous system stimulation is observed, followed 
by prolonged depression. The period of recovery is heralded by a return of the 
signs of stimulation. This sequence of events follows the classical pattern of 
induction and emergence from general anesthesia. The animals, however, are not 
anesthetized. They may show a reduction or absence of response to pain. How- 
ever, it is almost always possible to arouse them from the depressed state through 
adequate sensory stimulation. The simple procedure of righting a dog or monkey 
and placing him in the normal position of locomotion usually produces arousal 
of short duration. This procedure may, in fact, induce a period of hyperexcitation 
and a very brief return of almost normal behavior. If the dose is sufficient to 
cause initial excitation characterized by tremors or convulsions, these may return 
when the animal is subjected to forced arousal during the period of marked 
central nervous system depression. 
DMHP is the most potent of the synthetic THC derivatives we have tested. '~~ 
MOP has an almost identical spectrum of activity and is nearly as potent as 
DMHP. NAP, the parent compound of this class, is considerably less potent. In 
adequate doses, however, it possesses all the qualitative actions of the other two 
drugs. As a group, these drugs possess several additional interesting properties. 
They are effective orally, and the duration of CNS depression is roughly pro- 
portional to the magnitude of the administered dose. After single large doses of 
DMHP ( 10 mgl kg, i.v.) , dogs have been maintained in an unconscious state for 
five to six days and have recovered uneventfully. There is a marked reduction in 
body temperature, which is maintained during the phase of CNS depression. 
Elevating the body temperature by placing the dog in warm water can initiate 
behavioral arousal during the phase of CNS depression. 
Effects of A9-THC on Rat One-way Avoidance Behavior 
A total of 12 na'ive adult male Holtzman rats were given 50 trials a day for 
two consecutive days to achieve a 90% avoidance criterion in a one-way jump 
box. The apparatus used was an adaptation of that by Caldwell and coworkers9 
described by Tenen.*O The behavioral parameters used were as follows: The con- 
ditioned stimulus (CS) was a five-second presentation of four 7.5-watt red lights 
with the simultaneous presentation of an escape ledge. At the end of five seconds, 
the CS overlapped with a five-second unconditioned stimulus (US) that con- 
sisted of 1 ma 60 Hz electric shock delivered to the grid floor. When tha subject 
jumped on the ledge, the sequence was terminated. A 30-second ledge rest 
period then ensued. If at the end of this time the animal still persisted in sitting 
on the ledge, he was automatically pushed off by an electromechanical moving 
wall. Random intertrial intervals were maintained with a mean of 30 seconds 
and a range of 15-60 seconds. 
All drugs were given intraperitoneally (i.p.) following a 10-trial warmup 
session. After injection a five-minute rest period was allowed before the animals 
were given another 50 trials. The entire session lasted approximately one hour. 
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FIGURE 1.  Doseeffect relation of AO-THC on rat one-way avoidance and escape behavior. 
On the y-axis are plotted the mean blocked responses for 3 rats/point, 50 trials/rat. On the 
x-axis is plotted the dose of AO-THC in mg/kg given i.p. Note that there is a marked separation 
of the blocked avoidance and escape responses. 
Ae-THC was made with use of a 4% Tween-20 or -80 suspension from an ori- 
ginal 99% ethyl alcohol solution. The method of preparation was as follows: 
The desired amount of Ae-THC in 95% ethyl alcohol was placed in a test tube. 
The ethyl alcohol was removed with a rotary evaporator (Buchler), with the 
water bath set at 45' C. When the ethyl alcohol evaporated, the THC remained 
in the bottom of the test tube as a thick, dark brown resin. The total time of 
evaporation usually was two to four minutes. Tween 20, 4% of the final volume, 
was then added and thoroughly mixed with the THC in a Vortex shaker. The 
desired volume of 0.9% NaCl was then added to the THC-Tween mixture with 
gentle heating and shaking. The final suspension looked milky white. It was 
used within 48 hours after placing in a refrigerator at 4' C. Before each injec- 
tion, the suspension was again shaken to insure homogeneity. Very recently we 
have prepared Ae-THC via a new method developed by Stark." The end product 
is an almost clear solution that seems to have a much smaller particle size. This 
method consists of dissolving 10 mg of THC in 20 ml of absolute ethyl alcohol. 
Then 20 ml of a 1% Tween-80-0.9% NaCl solution is added. The volume of 
this mixture is reduced by evaporation, as above, to a 20-ml solution containing 
0.5 mg/ml. This new technique was not used in the work described below. 
In FIGURE 1 are illustrated the doseeffect relations of Ae-THC on one-way 
rat avoidance behavior. On the y-axis is plotted the percentage of blocked re- 
sponses, either avoidance or escape, while on the x-axis, the dose given i.p. Each 
point represents the mean of 50 trials for each of three rats. It can be noted that 
doses between 3.2 and 32 are quite effective in reducing avoidance behavior. 
By contrast, escape behavior is much less depressed, as is generally observed with 
narcotic analgesics and neuroleptics on various avoidance tasks.I2 
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Eflects of Various THC Derivatives on Schedule-Controlled Behavior in the 
Pigeon 
In collaboration with Mrs. Mary Beth Black and Dr. James Woods, we have 
studied the effects of various THC derivatives on schedule-controlled behavior 
in the pigeon under a multiple fixed ratio 30 (FR 30) fixed-interval five minutes 
(FI 5)  schedule of food reinf~rcement. '~ Twenty-seven male and female white 
Carneaux pigeons weighing between 450 and 600 g when given free access to 
food and water were used. They were deprived to 80% of the free-feeding 
weights and maintained at this level. The animals were conditioned with grain 
seed to peck a transilluminated response key.14 Each pigeon was conditioned on 
an alternating multiple FR 30 FI 5 schedule, as has been used by many.l5 In 
the presence of a blue light, the 30th peck on the response key resulted in a 
five-second access to bird seed (FR 30). In the presence of a red light, the first 
response after five minutes also resulted in a similar access to seed (FI 5 ) .  A 
hold of 45 seconds regulated food presentations when no responding occurred. 
Session length was 40 food presentations or 40 limited holds, depending upon 
whether or not the animal responded. 
All drugs were suspended as described above. They were given intramuscularly 
(i.m.) 30 minutes prior to the experimental session. Control injections consisted 
of an equal volume of Tween-saline. Mean rate of responding during the FR 
and FI  periods were computed for the total session. Quarter-life was calculated 
for each session of the fixed-interval periods. 
One of the first problems was to determine if the animals could be given drug 
injections at weekly intervals without any accumulative or tolerance effects. It 
was soon obvious that tolerance development was a marked problem (see below), 
and therefore all legitimate dose-effect studies had to involve na'ive birds. The 
effects for three different animals for each dose are illustrated in FIGURE 2. On 
the y-axis is plotted the ratio of responding on the drug to vehicle control for 
FI, FR, and quarter life (QL) and on the x-axis dose. In general, the drug pro- 
duces a dose-related depression of key pecking. We are now studying the effects 
of even lower doses of Ag-THC. 
All three agents, A9-THC, pyrahexyl, and DMHP produced a marked decrease 
in rate of responding under both schedules, but F I  behavior was somewhat more 
sensitive. Doses of 0.1-10 mg/kg, i.p., were used and showed primarily increas- 
ing depression. 
Tolerance Development to the Behavioral Eflects of THC Derivatives 
It is widely believed that smoking marijuana does not produce tolerance. This 
belief was strengthened by Walton,I6 who reported that there was no tolerance 
to marijuana. In fact, hearsay reports from users suggest a sensitization upon 
repeated use. More recently, Seeversl' and the AMA Committee on Alcoholism 
and Drug Dependence's agreed with the concept that no tolerance or physical 
dependence has been demonstrated with Cannabis preparations. Longo and co- 
workers19 gave Ae-THC daily to rabbits in doses of 3 mg/ kg, and they showed no 
EEG or behavioral tolerance, by contrast with LSD-25. 
While there appears to be no good evidence of physical dependence on Can- 
nabis preparations, there is now considerable evidence of tolerance development, 
especially to pure THC derivatives in both man and animals. Williams and associ- 
atesZ0 studied the effects of acute and chronic marijuana and pyrahexyl (Syn- 
hexyl) on six former opiate users who had previously smoked marijuana. Pyra- 
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hexyl was given in self-chosen intervals for 26-3 1 days. The daily dose range of 
662,400 was taken orally in one to eight individual doses. About three hours 
after the initial dose of pyrahexyl, the subjects exhibited drowsiness, euphoria, 
dry mouth, injected sclera, increased laughter, and swollen eyelids. The patients 
became euphoric and garrulous and showed spontaneous laughter. Most reported 
that these effects were similar to marijuana but stronger. After four to six days 
the effects of the drug were less than on the first or second day. An increase in 
dosage of pyrahexyl caused a return of typical drug effects. During prolonged 
medication, the EEG showed a slowing of the dominant frequencies. Abrupt 
withdrawal showed no abstinence on the first two days. However, on the third 
day very mild effects were seen, such as restlessness, poor sleep, loss of appetite, 
and “hot flashes.” These authors did not feel that physical dependence could 
definitely be established, although tolerance development was obvious. 
Williams and colleagues20 also studied the effects of chronic marijuana smoking 
of material of unknown resin content but described as “good weed” by the users. 
Six subjects were allowed to smoke marijuana ad libitum for 39 days. The rela- 
Dose mg/kg 
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FIGURE 2. Dose-effect relation of AB-THC on a multiple F1 5, FR 30 key pecking schedule 
in pigeons. The mean ratio of key pecking/2-hour period on the two schedules for drug VS. 
vehicle control are given on the y-axis and the dose on the x-axis. The drug was given to drug 
naive pigeons, i.m. The effects for FI, FR, and FI quarter-life (QL) are shown. Note, in gen- 
eral, that the marked depressant effects with F1 behavior are somewhat more sensitive than 
with FR behavior. 
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tively slight increase in  the number of cigarettes smoked daily suggested that with 
these amounts rapid tolerance to marijuana does not develop. With both the 
pyrahexyl and marijuana the initial gaiety and loquaciousness lasted only a few 
days, but could be reelicited by increasing dosage. When cigarette smoking 
stopped suddenly, there were no abjective signs of abstinence, but all patients 
reported that they were subjectively more “jittery.” This study needs to be repli- 
cated with mariiuana of known A9-THC content. 
Both Cadinizl and Silva and coworkerszz demonstrated tolerance development 
to repeated injections of 20-25 mq/kq of Cannabis qxtract and 10 mg/kg of 
Ag-THC in rats on various behavioral tasks. McMillan and colleaguesZ3 have 
also reported marked tolerance development of As- and A9-THC when injected 
daily in increasing amounts to pigeons trained on a multiple schedule for food 
reinforcement. 
Quite independently, our laboratory has been involved in similar studies that 
indicate marked tolerance development to both naturally occurring and synthetic 
THC derivatives given to animals. These studies first began in the mid-1950s 
when various synthetic THC derivatives were studied for the Army Chemical 
Center. Hardman and  coworker^^,^ and Domino and coworkersz4 have recently 
summarized this research, which had remained classified for some 15 years. 
Hardman and associatesz5 observed that tolerance to the gross behavioral de- 
pressant effects of the potent synthetic THC derivative, DMHP, could be obtained 
in dogs and monkeys given repeated intravenous (i.v.) daily doses. After seven 
days of daily injections of DMHP, up to 1.0 mglkg, surviving dogs showed 
minimal depressant effects, with only a slight reduction in motor activity and 
ataxia. No cross-tolerance to morphine (3.0 mglkg, subcutaneously) was ob- 
served. After one week of daily DMHP, its abrupt cessation produced no obvious 
withdrawal symptoms. At the end of four weeks of abstinence, the response to 
1 mglkg, i.v., of DMHP was less profound than the initial response of the dogs 
to the drug. 
A series of Macaca mulatta monkeys was studied in a similar manner and 
showed tolerance development and no obvious withdrawal symptoms within 
24 hours after abrupt withdrawal one week after daily dosage. This study must 
be repeated with a longer dosage schedule and period of observation, in view of 
the Williams and coworkers report and the persistence of THC in the body. 
Monkeys showing gross behavioral tolerance also showed a diminished high- 
voltage, slow-wave EEG pattern as well. Tolerance to DMHP was partial, but 
also lasted for many weeks, just as in the dogs. DMHP in doses of 1 .O-2.0 mg/kg, 
i.v., failed to substitute for morphine in chronically morphine-dependent mon- 
keys, just as pyrahexyl failed to substitute for morphine dependence in man, as 
described by Himmelsbach.26 
Because these observations were made with a synthetic THC derivative 15 
years ago, we decided to pursue the problem further when Ae-THC became 
available. The AD-THC was available in limited quantities so we decided to study 
its effects in small animals such as the rat and pigeon. 
Tolerance Development to the Behavioral Eflects of Ag-THC on Rat One-way 
Avoidance Behavior 
Six rats were trained in a one-way avoidance box as described above. When 
animals reached a 90% avoidance criterion they were then given 20 mg/kg, 
i.p., A9-THC. As noted in FIGURE 3, this dose produced a marked decrease in 
avoidance behavior similar to that described previously (see FIGURE 1 ) .  Daily 
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administration of Ag-THC produced an obvious reduction of drug-induced be- 
havioral depressant effects. Inasmuch as the animals were given daily injections 
and runs in the jump box, the issue of behavioral vs. pharmacologic tolerance 
to As-THC remains confounded. Currently, with Dr. L. M. Newman, we are 
attempting to determine which tolerance effect, behavioral or pharmacological, 
predominates. 
Tolerance Development to the Effects of Various THC Derivatives on Schedule- 
Controlled Behavior in the Pigeon 
McMillan and  coworker^^.^^ reported that AS-THC in a dose of 1.8 mg/ kg, 
i.m., depressed the rate of key pecking in pigeons on a multiple FR 30, FI 5 
schedule of food reinforcement. The rate of key pecking gradually returned to 
control levels after five to eight daily injections. Subsequently, tolerant pigeons 
given doses as large as 180 mg/kg three times per week continued to key peck 
at near-normal rates. These were lethal doses to nontolerant animals. Cross- 
tolerance to large doses (36 mg/kg, i.m.) of A* were also observed. CompoZ8 
has also reported tolerance development and cross-tolerance between azatetra- 
hydrocannabinol and pyrahexyl that persisted for months. 
In our own laboratory we were concerned with the dose-effect relations of 
DMHP, pyrahexyl, and As-THC on the same behavior as described above. Stand- 
ard behavioral designs include one-week intervals of drug administration to 
the same bird. Much to our surprise, pigeons given various THC at weekly in- 
tervals showed tolerance as well as cross-tolerance. Ag-THC ( 10 mg/ kg) , DMHP 
1 AVOIDANCE 
FIGURE 3. Tolerance development to the behavioral effects of AO-THC on rat one-way 
avoidance. The height of each bar represents the mean blocked responses and the small 
vertical line f S.E. of 6 rats, 50 trials/rat before and after daily AO-THC. The drug was given 
i.p. in doses of 20 mg/kg for 9 days. Note the marked tolerance development. 
Domino: Neuropsychopharmacologic Studies 173 
AVERAQE OF 3 BIRDS - I MWKQ 0 ... FR 


















BASELINE WEEK I 2 3 4 
FIGURE 4. Bar graph showing tolerance development to the behavioral effects of weekly 
As-THC on multiple FI 5 FR 30 key pecking in the pigeon. The mean 2 S.E. control 
rates of FR and FI key pecking for three different pigeons after Tween-20 saline alone are 
given as 100%. AO-THC in a dose of 1.0 mg/kg, i.m. given once/day at weekly intervals caused 
a marked decrease in the percent rate of responding, as noted. After 1-8 weeks, tolerance 
development is progressively apparent. 
(0.3 mglkg), and pyrahexyl (10 mg/kg) were given i.m. once per week for 
seven weeks. All drugs produced a marked decrease in rate of responding on both 
the FR 30 and FI 5 schedule, as described above. Tolerance was observed with 
each successive drug administration. This is illustrated in FIGURE 4 for three 
pigeons given 1.0 mg/kg, i.m., of AO-THC at weekly intervals. The mean control 
rate of key pecking on a FR and FI schedule after the vehicle control is given 
as 100%. do-THC given once the first week in a dose of 1 mg/kg markedly de- 
pressed FR and FI behavior. When given once per week on succeeding weeks 
(2-7), tolerance developed rapidly and seemed maximal by the eighth week 
under these circumstances. Cross-tolerance to the synthetic derivatives was 
tested on the eighth week in other animals. Pyrahexyl exhibited cross-tolerance 
with AO-THC. Similarly, cross-tolerance was exhibited between DMHP and 
One very interesting effect was obtained when the dose-effect responses of 
naive and tolerant pigeons were compared, as illustrated in FIGURE 5. The tol- 
erant birds were given ascending or descending doses in sequence with a high dose 
of 10 mg/kg Ag-THC. As expected with tolerance development, there is a shift 
in the dose-effect curve to the right. Tolerance was more marked at the descending 
weekly series of injections than at the ascending series. This research is now in 
the process of being published elsewhere in more detail by Black and c o l l e a g ~ e s . ~ ~  
Ag-THC. 
Effects of As-THC on Brain Acetylcholine Content 
In view of the fact that Ag-THC produces predominant sedation, it seemed 
of interest to determine its effects on brain acetylcholine ( ACh) . There is some 
data in the literature on its interactions with the peripheral cholinergic system. 
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Gill and coworkers30 reported AQ-THC either to have no effect or to potentiate 
the action of ACh on the guinea pig ileum. Layman and on the other 
hand, claimed that both AQ-THC and cannabidiol reduced the guinea pig ileum 
response to both ACh and histamine at 3.18 X lo-' M, suggesting a general 
depressant effect. On the other hand, these compounds had no effect on the rat 
phrenic nerve diaphragm preparation, or on ACh-induced contractions of the 
frog rectus abdominis muscle. These THC derivatives given i.p. also had no effect 
on the pre- or postganglionically stimulated nictitating membrane. Thus, the 
nicotinic effects of ACh do not seem to be affected, but the muscarinic effects 
of ACh may be in the guinea pig ileum preparation. 
Effects in Mice 
Adult male pure-bred mice weighing from 20-26 g of the DBA/J2 and C3H/ 
HeJ strain were obtained from the Jackson Laboratories, Bar Harbor, Me. The 
animals were on a 12 midnight-7 a.m. dark and 7 a.m.-12 midnight light cycle. 
They were given AQ-THC or Tween-80-saline vehicle, i.p., and sacrificed one- 
half hour later. The brain, minus the cerebellum, was removed and bioassayed 
for ACh with use of a modification of the method of Stone,32 as described 
previously.33 
As illustrated in TABLE 1, both strains of mice had similar control levels of 
brain ACh. The Tween-80-saline vehicle caused a slight but insignificant increase 
in brain ACh. Increasing doses of A9-THC also caused a slight but progressive 
increase in brain ACh that was significantly above vehicle control levels (P < .05 ) 
FIGURE 5. Dose-effect relations of Ae-THC on multiple FR 5 FR 30 key pecking schedule 
in drug-naive and tolerant pigeons. The data are plotted similar to those in FIGURE 2 for the 
naive animals. The tolerant birds were given ascending or descending doses in sequence with 
a high of 10 mg/kg of do-THC. Note the shift of the dose-effect curves'to the right expected 
with tolerance development. Note that for the ascending or descending dose series the drug 
was given at weekly intervals for 7 weeks. 
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TABLE 1 
DBA/JZ AND C3H/HEJ MICE 
EFFECTS OF AO-mC ON THE CONTENT OF BRAIN ACETYLCHOLINE  
Dose 
nMol ACh/gm +- S.E. 
DBA/JZ N C3H/HeJ 
Behavior N P Value 
controls active 8 18.1 f 1.1 8 18.2 f 1.1 - 
tween-80 saline 
controls active 14 20.8 f 1.5 - - N.S. 
5 mg/kg active 9 19.4 f 1.3 - - N.S. 
10 mg/kg depressed 11 2 3 . 2 f  1.3 - - N.S. 
comatose. 6 25.5 f 3.1 I 26.3 f 2.8 <.05 50 mg/kg 
when the mice lost their righting reflex and were comatose. It is well known that 
most central nervous system depressants in doses producing coma elevate brain 
ACh.34 Thus the question of whether As-THC is producing these effects secon- 
dary to CNS depression becomes paramount. 
Effects in Rats 
An important measure is not steady state, but turnover of brain ACh. The 
turnover of any compound can be determined only if certain rigid criteria are 
f ~ l f i l l e d . ~ ~ . ~ ~  One technique is to use a drug to stop synthesis of the biogenic 
compound of interest. This effect must be immediate to obtain meaningful 
quantitative data. Such an approach is not really feasible with use of hemi- 
cholinium-3 (HC-3) as a cholinergic antisynthesis agent. Inasmuch as the mech- 
anism of action of HC-3 is still debated, and it certainly does not act instantane- 
ously, it cannot be used in measuring true brain ACh turnover. It can, however, 
be used as a tool to measure relative rates of ACh depletion if its rate of action 
is constant. We have studied the effects of As-THC on brain ACh depletion 
following intraventricular (i. vent.) HC-3 given to rats. 
Young albino male Holtzman rats were used from 20-30 days of age. The 
animals were on a 12 p.m.-7 a.m. dark and 7 a.m.-12 p.m. light cycle. HC-3 
bromide was given i. vent., with use of diethyl ether anesthesia. A9-THC was 
given i.p. simultaneously with the injection of HC-3 i. vent. and termination of 
anesthesia. Animals were given various doses of HC-3 and equimolar NaBr and 
were sacrificed by guillotine. The brain, minus the cerebellum, was removed 
and bioassayed for ACh as described above. All drug dosage was calculated 
as base. 
A dose of 20 p g  total of HC-3 produced about a 60% depletion of brain ACh 
one-half hour after i. vent. injection, with a relatively low rate of mortality. 
Five minutes after this dose of HC-3, brain ACh dropped rapidly from a control 
postether mean -+ S.E. of 18.9 * 0.5 to 13.8 t 0.3 nmoles/g for a depletion 
rate of 5.1/5 min or 1.2 nmoles/g/min. A second slower rate of ACh depletion 
occurred from 13.8 -t 0.3 to 10.1 f 0.1 from 5 to 30 minutes postinjection with 
a rate of 3.7/25 or 0.15 nmoles/g/min. These data are in agreement with those 
of Hebb and  coworker^,^^ for intracaudate and with S la teF  for i. vent. injections 
of HC-3. 
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Groups of eight young rats were given i.p. Ag-THC alone and Ae-THC plus 
20 p g  i. vent. HC-3 and sacrificed 30 minutes later each morning b?tween 
8:30 and 9:30 a.m., and brain ACh was measured that day. The data obtained 
are plotted as a bar graph in FIGURE 6. The mean 2 S.E. control level of brain 
ACh of 18.1 f 1.3 nmoleslg is illustrated by the upper stippled bar and that 
following HC-3 alone (10.1 f 0.1 nmoledg) by the lower hatched horizontal 
bar. The open vertical bars represent the mean level of brain ACh alone, and 
the slanted vertical bars that after he-THC plus HC-3. A Tween-20 saline ve- 
hicle control given i.p. showed no significant change in brain ACh, compared 
with noninjected rats. The open vertical bars should be compared to the upper 
horizontal stippled bar for the effects of A9-THC on steady state brain ACh, and 
the slanted vertical bars should be compared with the lower horizontal bar for 
the drug effect on HC-3-induced depletion. Group comparison student t tests 
were determined. The asterisks indicate the significance probabilities. It can be 
noted that only 32 mg/kg of Ag-THC given i.p. produced a slight but significant 
(P <.01) increase in steady state brain acetylcholine. This is a dose that pro- 
duces marked depression of one-way avoidance behavior (see above). Smaller 
doses of Ag-THC alone have no significant effect on brain ACh. Following 
As-THC plus HC-3 in doses of 3.2 i.p. and 20 pg i. vent., no significant differ- 
ences in brain ACh were observed from non-Ag-THC-injected animals. However, 
following 10 and 32 mg/kg of Ag-THC there was antagonism of the expected 
HC-3-induced reduction of brain ACh (P <.01). The effects at 10 mg/kg of 
Ag-THC are similar to those seen with morphine, whereas those at 32 mg/kg 
are similar to those seen with pentobarbital and chlordiazepoxide. 
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FIGURE 6. Effects of Ae-THC on brain acetylcholine depletion following i.vent. hemi- 
cholinium-3 in young rats. The mean f S.E. brain ACh of control rats 25-30 days old is given 
by the upper horizontal bar and that after 20 fig i. vent. HC-3 by the lower horizontal bar. The 
open vertical bars represent the mean -C S.E. brain ACh ‘h hr after Ae-THC given alone Lp., 
and the slanted vertical bars represent that after Ae-THC i.p. and HC-3 i. vent., as noted. All 
data are expressed as mean zk S.E. brain ACh in nMol/g. P values are ** < .01 student t test 
group comparison. The small vertical lines represent f S.E. At least eight animals are in each 
group. 
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EFFECT OF Ao-THc ON ACETYLCHOLINE RELEASE FROM CAT CEREBRAL CORTEX* 
ACh Output (ng/cmz/lO min) 
Dose Percent 
mgfkg i.v. Before A9-THC After AQ-THC Variatloa 












































11.0 14.3 5.3 -63% 
Data taken from Domino & Bartolini.'l 
Effects on Cortical Release of Acetylcholine 
A considerable literature exists on the neocortical release of ACh with various 
physiologic and pharmacologic conditions. It is well known that amphetamines9 
and scopolamine40 increase and pentobarbital decreases40 neocortical release of 
ACh. Thus, it would be of interest to know what Ag-THC would do in view of 
its mixed stimulant and depressant effects. The cortical release of ACh therefore 
was studied in brainstem transected posthalothane anesthetized cats with use of 
the technique of Bartolini and P e ~ e u . 4 ~  The ACh was bioassayed on the dorsal 
leech muscle. This research was done in collaboration with Dr. Bartolini and 
his wife, Rosalia. A total of six cats was used. Release of ACh was measured 
from the suprasylvian gyrus and bioassayed. The ACh output was expressed in 
ng/cm2/ 10 min. This research will be published in detail shortly.41 
TABLE 2 lists the data obtained following the i.v. administration of AQ-THC 
in doses of 0.5-11 mglkg. Small doses of AQ-THC of 0.5 mg/kg showed very 
marked individual variations in the percent release. Two animals showed a 
definite increase and one a slight decrease in ACh release, with a mean change 
for the group of + 19 % . Larger doses of he-THC showed progressive decreases 
in ACh release typical of central nervous system depressants such as pentobarbi- 
tal or morphine. In addition, the neocortical EEG of these pretrigeminal brain- 
stem-transected cats showed high-voltage slow waves after such large doses of 
The results of one experiment with an animal given AQ-THC and d-ampheta- 
mine as a possible antagonist on acetylcholine release are plotted in bar graph 
form in FIGURE 7. This was a post-halothane pretrigeminal brainstem transected 
cat who showed a high basal release of ACh in the order of 25-30 ng/cm2/10 
minutes from the suprasylvian cortex. A dose of 0.5 mg/kg of AQ-THC caused 
a transient increase followed by a gradual decrease. ACh release was reduced 
AQ-THC. 
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FIGURE 7. Effects of AO-THC and d-amphetamine on neocortical release of acetylcholine. 
The height of each bar represents the ng/cm*/lO min of ACh released from the somatosensory 
cortex of a pretrigeminal brainstem-transected cat. In this cat, AO-THC in a dose of 0.5 mg/kg, 
i.v. caused a negligible change in ACh release within experimental error. However, 3 mg/kg, 
Lv., produced a marked decrease, which was antagonized by 2.5 mg/kg of d-amphetamine, 
as noted. 
even further by 3.0 mglkg. At the same time, the neocortical EEG showzd slow 
wave activity. d-Amphetamine in a dose of 2.5 mg/kg, i.v., caused EEG activa- 
tion as well as a return of ACh release to control levels. 
Electroencephalographic Studies in Animals 
Depending upon dose and species, marijuana derivatives have a wide spectrum 
of electroencephalographic (EEG) effects. Bose and associates42 reported that 
acute i.p. injections of Cannabis resin in rabbits caused an initial EEG activation 
followed by high-voltage sharp waves. Bicher and Mechoulam43 observed that 
8 mg/kg of racemic As- and Ag-THC caused restlessness, a lowering of arousal 
threshold to reticular stimulation, and EEG activation in rabbits with chronic 
indwelling brain electrodes. On the other hand, Longo and coworkers1g and 
Lipparini and associates@ showed in rabbits with chronic indwelling brain elec- 
trodes that pure ( - )  As- and A9-THC abolished hippocampal &waves and 
gave rise to neocortical high voltage spikes and slow waves. While these results 
do not agree with those of Bicher and Mechoulam, they agree with those of 
Boyd and Merritt,"s who showed that DMHP caused a decrease in EEG and 
behavioral arousal in the cat. Masur and Khazan46 showed that in rats Cannabis 
extract and A*-THC caused EEG polyspike discharges during both the awake 
state and REM sleep on both acute and chronic administration. 
Our own research in this area was primarily in the acute and chronic dog and 
chronic monkey with brain electrodes. Most of our studies were with DMHP 
and fewer with MOP, and very recently with A9-THC. Recently some of these 
studies have been reported.24 The EEG effects in acute dogs were studied after 
i.v. administration. Mongrel dogs were immobilized by decamethonium or galla- 
mine and placed on continuous artificial respiration. All surgery was performed 
under local anesthesia. Insulated steel nails were placed through the scalp into 
the calvarium for recording the electrical activity of the cerebrum. Care was 
taken to avoid passing through the posterior lamella. Electrical activity from the 
neocortex was recorded with a Grass electroencephalograph. The electrocardio- 
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FIGURE 8. Effects of DMHP and d-amphetamine on the neocortical electroencephalogram 
of the dog. Bipolar EEG recordings were taken in a locally anesthetized, decamethonium im- 
mobilized dog on  artificial ventilation. A = control. B = one hr after 100 pg/kg of DMHP, 
i.v. Note high-voltage, slow-wave bursts with spikes and bradycardia. C = same as B, but with 
a loud noise presented at  the arrow (t). D = After d-amphetamine, .I mg/kg, i.v. 1 = left 
frontal, 2 = rt frontal, 3 = left parietal. 4 = rt parietal cortex. B.P. = arterial blood pressure 
in mm Hg. EKG lead 11. 
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gram, lead I, and the femoral arterial blood pressure were recorded simultane- 
ously. Seven dogs were utilized to obtain control EEG data. The dogs received 
either one ml of a 95% solution of ethyl alcohol or a comparable volume of 
isotonic sodium chloride solution and were observed for several hours. The usual 
EEG pattern observed consisted of low-voltage, fast-frequency waves charac- 
teristic of an awake, unanesthetized dog. Over a two-hour period, slow-wave 
bursts would occasionally appear. These were quickly converted by noise or 
other afferent stimuli to a low-voltage, fast-frequency EEG. Control animals, 
therefore, show electrical correlates of drowsiness or sleep that are quickly re- 
versed to a state of wakefulness by certain afferent stimuli. 
Seven dogs received varied doses of DMHP administered i.v. in 95% ethyl 
alcohol. With doses of 50 pg/  kg, sleep spindles were occasionally observed. 
However, such spindling was also common in the control animals. After 100 
pg/kg, the high-voltage slow waves were prolonged and were more frequent 
than in controls. The EEG record of one such experiment is shown in FIGURE 8. 
The upper tracing, A, represents the control EEG of the dog one hr after surgery. 
One hour after 100 pg/kg of DMHP, the high-voltage slow waves were pro- 
longed and alternated frequently with low-voltage, fast-frequency activity (see 
B, FIGURE 8). The observed high-voltage, slow-wave bursts of twelve cycles per 
second could readily be converted to a low-voltage, fast-frequency EEG pattern 
by afferent stimuli such as noise (see C, FIGURE 8) .  Since increased afferent 
activity resulted in EEG activation, it was postulated that drugs that stimulate 
the brainstem-activating system would antagonize the EEG effects of DMHP. 
As shown (see D, FIGURE 8) ,  d-amphetamine (100 pg/kg) does antagonize the 
slow-wave activity induced by DMHP. The EEG pattern obtained is almost 
indistinguishable from the control (compare A and D) . 
The effect of large doses of DMHP (1.0 mg/kg) is illustrated in FIGURE 9. 
Tracing A represents a normal low-voltage, fast-frequency control pattern. The 
frequency of spindling and slow waves increased about one-half hour after 
drug administration. One hour after the drug, generalized slow-wave activity 
with frequent spindle bursts were observed. Auditory stimuli were completely 
ineffective in producing EEG arousal during this period (see B, FIGURE 9). 
Exceedingly painful stimuli, however, such as pinching the testicles, resulted in a 
barely effective EEG arousal. High-voltage spike-like and slow waves are also 
seen (see C, FIGURE 9). Within a minute, the spontaneous electrical activity 
returned to a high-voltage, slow-wave pattern. DMHP-induced high voltage, 
slow wave and spikes could be partially reversed by psychomotor stimulants 
such as d-amphetamine in doses of .l-1.0 mg/kg, i.v. Although there was a 
definite EEG antagonism, the response after amphetamine was not the same as 
the very fast-frequency, low-voltage activity observed in the control tracing. Thus, 
the EEG antagonism was not complete. 
Four dogs received MOP, i.v., in doses of 0.5-1.0 mg/kg. Occasionally, alpha- 
like slow waves were observed, but the predominant character of the EEG was 
a low-voltage, fast-frequency pattern. After an additional 1 .O mg/ kg, marked 
high-voltage slow waves and spikes were seen. At this time, auditory stimuli 
were barely able to produce EEG activation. Fewer high-frequency waves were 
observed at this time than during the control tracing. In addition, there was a 
delay in the onset of arousal. After d-amphetamine ( 1 .O rug/ kg) , an incomplete 
antagonism of the slow-wave activity induced by MOP was observed. Thus, 
the acute EEG changes induced by MOP were very similar to DMHP but 
slightly less potent. Very recently, we studied AO-THC in similar preparations. 
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The EEG changes were quite similar, but the drug was less potent than these 
synthetic derivatives in doses of 0.5-10 mg/kg, i.v. 
HUMAN STUDIES 
Gross Behavioral and Neurologic Effects of Marijuana Smoking 
To date, we have been involved in three different studies with marijuana 
smoking in normal volunteers over the past three years. Perhaps these studies 
emphasize more than anything else the basic pharmacologic principle of dose- 
effect. It is obvious that unless the concept of dose is constantly considered, 
marijuana effects vary from a very mild intoxication or reversible organic brain 
syndrome to frank hallucinations, some pleasant and others frightening enough 
to induce a panic reaction and, with large amounts, stupor and semicoma. Our 
first study was in collaboration with Dr. Caldwell and Dr. Myers and has been 
reported p rev io~s ly .4~-~~  We were concerned with the effects of marijuana smok- 
ing to an endpoint of a “subjective high” on auditory and visual sensory thresh- 
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olds. Twenty experienced marijuana users were subdivided into a control and 
experimental group. The control group smoked alfalfa cigarettes in a pretest ( C , )  
and posttest (C2), while the experimental group smoked alfalfa in the pretest 
(El) and marijuana in the posttest (E2). A comparison of the mean changes in 
sensory thresholds between C ,  and C2 was a measure of practice effect during 
testing. A comparison of the mean change in El vs. Ez and C2 vs. Ez was a 
measure of the effects of marijuana. All tests were conducted with the subject 
sitting in a totally dark, soundproof, air-conditioned room. All cigarettes con- 
tained 300 mg of material. The crude marijuana was obtained from Dr. Scigliano 
from NIMH and was said to contain 1.3 12% A9-THC, but on reanalysis months 
later was found to contain .51% (courtesy of Dr. Wall) and 0.20% (courtesy 
of Dr. Forney). Our users reported it to be “good stuff,” and were allowed to 
smoke on an ad libirurn schedule until a subjective endpoint of a “high” was 
achieved. The results of this study were mostly negative, as noted in TABLE 3. 
There was no change in the visual brightness test at 2.4 and 4.8 foot candles, 
auditory amplitude threshold, auditory frequency threshold, and auditory decibel 
threshold. In only one aspect of the auditory amplitude difference threshold test 
did the marijuana smokers perform more poorly. The only consistent physiologic 
change was a slight increase in heart rate. 
The second study with the same batch of NIMH marijuana was conducted in 
collaboration with Dr. Rodin and Mr. Porzak and has also been reported.60 
Ten healthy freshmen medical students who had had previous experience with 
marijuana were allowed to smoke the 1.312% NIMH marijuana to their usual 
“high.” On the average, two to three cigarettes were consumed per subject. On 
neurological examination, there was nothing significant noted except slight 
improvement of vibratory sense. Mental status examination showed a slight de- 
crease in intellectual efficiency, some excess jocularity, a slight loosening of 
TABLE 3
LACK OF SIGNIFICANT DIFFERENCES IN MEAN PERFORMANCE S ORES FOR ALFALFA AND 
MARIJUANA GROUPS FOR VISUAL AND AUDITORY DISCRIMINATION MEASUREMENTS* 
First Test Session Second Test Session 
Variables Control Experimental 
(%Fa) ( E x ,  
Visual brightness test 
2.40 foot candle standard 2.25 2.51 
4.80 foot candle standard 4.09 4.93 
difference threshold 1.46 1.71 
point of subjective equality 14.56 14.40 
Auditory amplitude threshold test (decibels) 









Auditory frequency threshold test (cycles/sec) 
difference threshold 3.64 4.06 2.53 3.79 
point of subjective equality 1001.67 1001.24 1000.88 1000.05 
constant error +1.67 +1.24 +0.88 +0.05 
Auditory threshold test (decibels) 75.11 73.83 75.87 76.14 
* Data taken from Caldwell ef ~ 2 1 . ~ ~  
t t = 3.25, P < .01. Note that the threshold was increased for the second test session for the 
marijuana subjects when compared with the second test controls. All other test results were not 
significantly different. 
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FIGURE 10. Photograph of the eye before and after marijuana smoking. The pupil size and 
distance between the lids are given. Note marked ptosis after subject is “stoned.” 
association, and a slight short-term memory loss, suggesting a mild organic brain 
syndrome that was fully reversible. Bender-Gestalt drawings were executed 
slightly more poorly after marijuana. Visually evoked cerebral responses were 
unchanged, but EEG a-rhythm showed a slight shift toward a lower frequency 
(see below). No hallucinations were observed with this particular batch of 
marijuana. 
Subsequently, we obtained from Dr. Scigliano of NIMH marijuana that was 
chemically extracted so as to contain 0% AQ-THC, as well as batches containing 
1.5 and 2.9% AQ-THC. We are conducting a series of behavioral and pharma- 
cological studies with these materials and will report our data in the near 
f ~ t u r e . ~ l - ~ ~  So far, about 16 student volunteers have been given the 2.9% AQ-THC 
marijuana and allowed to smoke to the point of refusal in order to obtain a more 
complete dose-effect curve. To date, we have had about four subjects who had 
visual and/or auditory hallucinations and one very severe panic reaction. An- 
other two subjects smoked to the point of stupor and semicoma. Most of the re- 
maining subjects found the marijuana experience most pleasant and reinforcing. 
Our research to date simply reaffirms what has long been known about the clinical 
descriptive pharmacology of marijuana as recently reviewed in comparison with 
other  hallucinogen^.^.^^ In spite of the fact that pharmacologically, LSD-25 and 
marijuana are quite different, we have observed a patient who had recurrent 
LSD-25 flashbacks triggered by marijuana smoking.5a 
Although conjunctival redness has long been mentioned as a consistent effect 
of marijuana smoking and was also observed in our studies, a more dramatic 
finding is a slight ptosis of the upper eyelid that characteristically occurs in the 
really “stoned” smoker. This is evident from the before and after photographs 
in FIGURE 10. 
Cardiovascular Eflects of Marijuana Smoking 
Many investigators have observed that marijuana smoking or THC derivatives 
in man cause a significant increase in heart rate.5751 Manno and coworkersm 
and Renault and associatesa1 showed that the heart rate increase is highly dose- 
related. We have just completed an analysis of our data from two studies in 
which a similar dose-related increase is highly significant.62 
This study was performed in two parts. In 1969 ten subjects took part in a 
low-dose (assumed to be 0.5% AQ-THC as a median figure) marijuana study 
and then in a single-blind placebo (0% AQ-THC) study. In early 1971, 15 
different subjects took part in a high dose (2.9% AQ-THC) marijuana study. 
All subjects were males between the ages of 21 and 33. All had smoked marijuana 
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previously, but only 4 of 10 in the low-dose study and 2 of 15 in the high-dose 
study were daily users. One of the subjects in the high-dose study was able to 
tolerate a large dose (30 mg A9-THC) with little change in his outward behavior 
or conversation. The other 14 subjects reported that they were “as high or higher 
than ever before” during the high-dose marijuana study. All marijuana was 
administered as 300-mg cigarettes, which were smoked to the shortest possible 
butt. Butts were weighed to determine the dose smoked. In the low-dose study, 
subjects smoked from two to five cigarettes. In the high-dose study, subjects were 
instructed to smoke until they were as high as they had ever been on marijuana 
and felt they could not smoke any more. This required from one to four ciga- 
rettes. Subjects were told to inhale deeply and to let none of the smoke appear 
in the exhaled air. No corrections were made for pyrolysis, exhaled smoke, or 
cigarette smoke burned but not inhaled. 
Blood pressure was measured at least three times before marijuana was 
smoked, in order to obtain a stable baseline. It was recorded three times again 
within one-half hour after smoking. Diastolic pressure was recorded at the 
mufling of the Korotkoff sound. The difference in means of the blood pressures 
before and after marijuana is reported as the change in blood pressure. 
Pulse rate was recorded from a continuous polygraph record in those subjects 
who did not have complete EKG’s. The change in pulse rate is the difference 
between a baseline rate and the highest rate obtained within one hour of smoking 
marijuana. Dose of Ag-THC was calculated as total available in the cigarettes 
smoked, and not as that inhaled. It is well known that pyrolysis reduces the 
maximum amount of Ag-THC available. 
As shown in FIGURE 11, the increase in heart rate after smoking marijuana is 
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FIGURE 11. Dose-effect relations of marijuana smoking on heart rate. Adult male volunteers 
were given various amounts of marijuana of varying A0-mC content. The maximal increase 
in heart rate above control is given on the y-axis, and the total amount of AO-THC in the 
cigarettes on the x-axis. Each point represents an individual subject. The coefficient of correla- 
tion is 0.8 for which P < .001. 
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heart rate is 0.8, for which P <0.001. One subject, a daily user of marijuana, 
seemed to be extremely tolerant of the psychic effects. However, his heart rate 
increased from 55 to 120 after a 30-mg dose. 
The systolic blood pressure was significantly elevated in subjects receiving 
more than 10 mg marijuana, P <O.Ol on the Wilcoxin sign test for differences 
in related samples. The rise in systolic blood pressure appeared to be dose-related, 
although the coefficient of correlation was only 0.3 and the P value <0.10. 
The diastolic blood pressure was also significantly elevated after marijuana 
smoking, P <0.02 on the Wilcoxin test. For the diastolic pressure data, the 
coefficient of correlation of the loglo dose response curve was only 0.3. 
The data from the single-blind placebo extract experiments showed no signifi- 
cant changes in heart rate or blood pressure. Calculation of the marijuana 
dosage on a mg/kg basis using the subjects’ weights did not reduce the variation 
in the data. Two of our subjects showed premature ventricular contractions after 
marijuana smoking similar to those seen in susceptible nicotine tobacco and 
coffee users. 
Electroencephalographic Effects of Marijuana and Derivatives 
The first major study on the effects of acute and chronic pyrahexyl and mari- 
juana in human users was that reported by Wikler and Lloydes and Williams and 
coworkers. Single doses of oral 30 mg and 120 mg of pyrahexyl did not change 
the a-frequency significantly. In four of eight subjects the a-percentage de- 
creased. On continuous daily medication there was a significant decrease in 
a-frequency in three of five subjects with variable changes in a-percentage. Two 
subjects showed A-wave changes that returned to normal four days after cessa- 
tion of pyrahexyl administration. These same investigators studied the effects of 
marijuana smoking of unknown resin content under similar conditions. After 
acute marijuana smoking, no significant effect on a-frequency was observed, 
although a-percentage was usually decreased. 
In all cases muscle artifact increased in the EEG recordings. After continued 
daily smoking of marijuana, four of six subjects showed a slight decrease in 
a-frequency that was marked in only one case. Alterations in a-percentage were 
also variable, with three of six showing an increase, two of six a decrease, and 
one no change. By contrast with the single study of smoking one to four mari- 
juana cigarettes, muscle activity was not markedly increased during the con- 
tinuous smoking experiments. 
More recently, in collaboration with Dr. Rodin, we reexamined the effect of 
smoking marijuana cigarettes on the EEG of 10 freshman medical students who 
admitted to long-term use of m a r i j ~ a n a . ~ ~  After obtaining baseline controls, the 
subjects were given as many marijuana cigarettes as they desired to reach their 
usual “high.” On the average, two or three 300-mg cigarettes were consumed 
(870 * 80 mg). The marijuana used was initially assayed to contain 1.312% 
AB-THC. However, as discussed above, independent assays by Dr. Wall (0.5%) 
and Dr. Forney (0.2%) done over a period of six months showed a progressive 
reduction in AB-THC content of this marijuana kept in a safe at room tempera- 
ture. Data acquisition for computer analysis was done immediately after the 
subject had reported he had achieved his “high.” On visual inspection it was 
impossible to distinguish the premarijuana from the postmarijuana EEG, al- 
though there was a suggestion that after smoking there was a more persistent 
a-rhythm and possibly a slight slowing of the a-frequency. Power density 
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spectral analysis confirmed this impression, indicating a slight shift downward 
in the a-rhythm. This finding was statistically significant ( P  < .05).  
In the past six months we have had an opportunity to replicate some of these 
findings in another study with Mr. Porzak and Dr. Kovacic. A total of five 
experienced marijuana smokers were given up to four 300 mg 2.9% AQ-THC- 
containing marijuana cigarettes or a comparable amount of THC-extracted 
material. Grass silver electrodes were placed in accordance with the 10-20 
International Electrode System.64 Electrical potentials were obtained from F3 
(frontal), Cf (central), P3 (parietal) and 01 (occipital) to both ears, which 
served as a reference. All EEG recordings were made on the left side of the head. 
A Grass polygraph was used for amplification and recording. The data were 
recorded on analog tape, and selected portions were digitized for computer 
analysis. The procedure was to digitize one or more 60.5 second recordings at 
128 samples/second for each subject/condition. With use of the standard Lafa- 
yette Clinic Computer Program,65 power frequency spectra estimates were ob- 
tained with 0.25 Hz resolution. By using the half-height center as a measure of 
the a-peak frequency, the shifts shown in FIGURE 12 were obtained. For two 
subjects, a-peak frequency measures were obtained for extracted marijuana as 
well. EEG recordings were compared before and after smoking to the point of 
refusal of the marijuana. In FIGURE 12 are shown the average half-height a- 
center frequency shift in which the after-before difference in Hz is expressed. It 
can be seen that there is a very slight tendency for a 0.3-0.6 decrease in a-fre- 
quency in 4/5 subjects smoking active marijuana in contrast to extracted, which, 
on the Wilcoxin’s one-tailed test, was marginally statistically significant (P < .06). 
While these are not very convincing data, the indications are that there is a slight 
a-shift associated with marijuana smoking. This shift cannot be visualized easily 
in the actual record. In FIGURE 12 also are plotted the EEG data of Williams and 
coworkers in subjects who smoked marijuana continuously. Their data show 
very similar trends to our computerized approach. One can conclude that an 
impartial computer analysis of EEG data offers information similar to that of 
scientists who very carefully “eyeball” their records. 
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FIGURE 12. Comparison of a-frequency EEG shifts in marijuana smokers. The published 
data of Williams and coworkers*o of 6 subjects who smoked marijuana daily to 5 of our sub- 
jects who smoked up to four 2.9% A~-THC 300-mg marijuana cigarettes to the point of refusal. 
In both cases the shift in the a-center frequency is given as the difference between after and 
before marijuana smoking. A negative difference indicates a slowing in the basic a-frequency. 
The solid bars indicate active marijuana and the open bars two of the same subjects smoking 
the same number of extracted marijuana cigarettes. With use of a one-tailed Wilcoxin’s test, 
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COMMENT 
After serving a pharmacologic smorgasbord, what can one conclude about 
Cannabis and its natural or synthetic THC derivatives? Perhaps what stands out 
most clearly is that these agents are primary depressants of central nervous 
system function. However, they possess a unique spectrum of pharmacological 
actions with only superficial relation to various other psychoactive drugs. The 
chemistry and pharmacology of marijuana are distinct from other central nervous 
system depressants, yet it shares some properties with ethyl alcohol, general 
anesthetics like nitrous oxide, and psychotomimetics like LSD-25. The recent 
report to the Congress on “Marijuana and Health” emphasizes this as welLBS 
Dosage level is all-important! In low doses these drugs produce an intoxication 
that in some ways resembles that of ethyl alcohol or low concentrations of nitrous 
oxide. There are, however, definite subjective differences. In TABLE 4 are sum- 
marized some of the comparative aspects of Ae-THC, ethyl alcohol, morphine, 
LSD-25, nitrous oxide and scopolamine and phencyclidine on various pharma- 
cological parameters. From a scientific point of view, there is great danger in 
presenting any such table because the question of dose and species is always a 
critical factor. If the reader accepts such limitations, it is obvious that A9-THC 
has its own peculiar spectrum of pharmacology. Whether it has therapeutic merit 
is impossible to answer affirmatively as yet. We do have available a large variety 
of sedatives, analgesics, etc. Only further research will tell whether he-THC and 
related compounds will remain of primary social, rather than medical, con- 
sequence. 
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